HC Wainwright Lowers Valneva (NASDAQ:VALN) Price Target to $18.00

Valneva (NASDAQ:VALN) had its price target lowered by research analysts at HC Wainwright from $19.00 to $18.00 in a research note issued to investors on Thursday,Benzinga reports. The brokerage presently has a “buy” rating on the stock. HC Wainwright’s target price suggests a potential upside of 288.77% from the stock’s previous close.

Valneva Stock Down 1.7 %

VALN opened at $4.63 on Thursday. The business’s 50-day simple moving average is $4.29 and its 200-day simple moving average is $5.80. The company has a debt-to-equity ratio of 0.70, a quick ratio of 2.25 and a current ratio of 2.78. Valneva has a one year low of $3.62 and a one year high of $9.50. The stock has a market capitalization of $376.24 million, a P/E ratio of -35.62 and a beta of 1.93.

Institutional Trading of Valneva

An institutional investor recently raised its position in Valneva stock. AlphaCentric Advisors LLC boosted its stake in Valneva SE (NASDAQ:VALN) by 33.7% during the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The firm owned 118,000 shares of the company’s stock after acquiring an additional 29,748 shares during the period. AlphaCentric Advisors LLC owned 0.15% of Valneva worth $717,000 as of its most recent SEC filing. 11.39% of the stock is currently owned by hedge funds and other institutional investors.

Valneva Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.